This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

J.C. Penney Gets $1.75B Loan Commitment: Ahead of the Ticker

NEW YORK (TheStreet) -- Struggling retailer J.C. Penney (JCP) received a $1.75 billion term loan commitment from Goldman Sachs (GS).

J.C. Penney said in a statement that the five-year loan will be backed by the department store chain's real estate and other assets. The company plans to release more terms of the loan in a filing with the Securities and Exchange Commission.

The company, which is trying to shore up capital and revamp its financial situation, also recently borrowed $850 million from its $1.85 billion revolving credit facility.

Under former CEO Ron Johnson, J.C. Penney endured a 25% decline in sales last year as Johnson tried a more upscale, "no sales or coupons" strategy. He has been replaced by Myron Ullman, who is taking the helm of J.C. Penney once again and is expected to return to the company's former strategy of discount pricing.

The new financing comes on top of the recent announcement that billionaire investor George Soros took a 7.9% stake in the company.






Chinese e-commerce company Alibaba Group has purchased an 18% stake in Sina's (SINA) microblogging service Weibo for $586 million.

The deal values Weibo at more than $3 billion.

Sina said the deal should generate $380 million in revenue for Weibo in the next three years, aiding the company in its quest to make the service more profitable.

Sina's U.S.-listed shares climbed 17% to $58.85 on the news.

Alibaba will also receive the option to buy up to 30% of Weibo within a stipulated amount of time as part of the agreement. According to Sina, Alibaba and Weibo will work together on things like data exchange, online payments and marketing.

Yahoo (YHOO) owns 23% of Alibaba Group.






Drugmakers Pfizer (PFE) and Merck (MRK) said they are embarking on the joint development of Pfizer's experimental type 2 diabetes drug, ertugliflozin.

The companies expect late-stage trials of the drug to start later this year. Pfizer has received $60 million in upfront payment and milestones so far and will be eligible for more payments based on certain clinical, regulatory and commercial achievements. Merck and Pfizer will share potential revenue and specific costs on a 60/40 percent basis.

Stock quotes in this article: JCP, GS, SINA, PFE, MRK, BMY, YHOO 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs